Efficacy News and Research

RSS

Task Force set to back CDC hepatitis C screening

Clinicians should consider screening for hepatitis C virus in all patients born between 1945 and 1965, the US Preventive Services Task Force says in draft guidance.

3 Dec 2012

New laser surgical technique appears to be safe and effective in treating epilepsy

A developing new laser surgical technique for epilepsy appears to be safe and effective and reduces hospital stays to one or two days, according to two research reports presented today during the American Epilepsy Society 66th Annual Meting at the San Diego Convention Center.

3 Dec 2012

Long-term hippocampal DBS effectively reduces seizures in experimental models

The results of the first reported study of deep brain stimulation (DBS) in an animal model for temporal lobe epilepsy (TLE) presented today at the American Epilepsy Society (AES) 66th Annual Meeting suggests that DBS may have potential as therapy for this common and often difficult to treat form of epilepsy.

2 Dec 2012

Loss of either T-bet or Eomes protein reduces immune system's ability to fight viral infection

When you get an acute infection, such as influenza, the body generally responds with a coordinated response of immune-cell proliferation and attack that rapidly clears the pathogen. Then, their mission done, the immune system stands down, leaving a population of sentinel memory cells to rapidly redeploy the immune system in the event of reinfection.

1 Dec 2012

Researchers study antimicrobial peptides in fish gills to find solution for blocking human infections

Living in an environment teaming with bacteria and fungi, fish have evolved powerful defenses against waterborne pathogens, including antimicrobial peptides located in their gills. Undergraduate researchers at Worcester Polytechnic Institute are studying the biology and the mechanics of one of those peptides with the hope they can use that knowledge to create engineered surfaces that kill bacteria responsible for foodborne illnesses and hospital-acquired infections.

1 Dec 2012

Tissue damage, disease severity in C. diff. infection associated with disruption of PPARγ pathway

Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the body's natural defenses into overdrive, actually intensifying illness while fighting infection.

1 Dec 2012

Study of hospital-acquired infection yields potential therapeutic target

30 Nov 2012

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.

30 Nov 2012

Studies demonstrate effectiveness of Nonin's EQUANOX Advance Model 7600 Oximetry System

Nonin Medical, Inc. announced today the publication of two separate studies that demonstrate the clinical efficacy of the company's EQUANOX Model 7600 Cerebral and Somatic Oximetry System in adult and pediatric patients.

30 Nov 2012

Only assess glaucoma drug efficacy after multiple testing

Intraocular pressure measurements may be insufficient to determine treatment effectiveness, even when repeated multiple times, show study results.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54th American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga.

30 Nov 2012

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

30 Nov 2012

Aduro completes enrollment in CRS-207 and GVAX pancreas cancer vaccine Phase 2 trial

Aduro BioTech, Inc. announces completion of enrollment in the Phase 2 clinical trial of the sequential administration of two cancer vaccines, Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine, in patients with metastatic pancreatic cancer.

30 Nov 2012

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Treatment with a novel agent that inhibits the activity of SIRT2, an enzyme that regulates many important cellular functions, reduced neurological damage, slowed the loss of motor function and extended survival in two animal models of Huntington's disease.

30 Nov 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

Efficacy News and Research

Task Force set to back CDC hepatitis C screening

New laser surgical technique appears to be safe and effective in treating epilepsy

Long-term hippocampal DBS effectively reduces seizures in experimental models

Loss of either T-bet or Eomes protein reduces immune system's ability to fight viral infection

Researchers study antimicrobial peptides in fish gills to find solution for blocking human infections

Tissue damage, disease severity in C. diff. infection associated with disruption of PPARγ pathway

Study of hospital-acquired infection yields potential therapeutic target

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Studies demonstrate effectiveness of Nonin's EQUANOX Advance Model 7600 Oximetry System

Only assess glaucoma drug efficacy after multiple testing

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

Aduro completes enrollment in CRS-207 and GVAX pancreas cancer vaccine Phase 2 trial

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

SLU study to use various assays for new TB vaccine development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News